Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Movymia

Unfolding the biosimilar landscape in Latin America

Cost containment and safety concerns mean an ongoing tussle between payers and regulators, with the latter gaining the upper hand

- PMLiVE

Current development and marketing of biosimilar monoclonal antibodies in Latin America

An in-depth table of biosimilar products in the region

Merck & Co’s Jürgen Polifka joins Cardiome

Will lead commercialisation in Europe of atrial fibrillation treatment Brinavess

- PMLiVE

Merck & Co fails to block generic Januvia in India

Court says Glenmark can sell cheap copy of diabetes drug

Agneta Brandt joins EMA as head of infrastructure

Joins as company prepares to move offices

- PMLiVE

Interview: Pierre Chancel, Sanofi Diabetes

The head of Sanofi Diabetes shares the company’s strategy to keep pace with the race against this ‘hidden disease’

- PMLiVE

EMA launches diabetes drugs safety review

Will investigate pancreatitis risks in two major drug classes

Sanofi reception

Sanofi to act as contract manufacturer for Transgene

French biopharma partners with its big pharma compatriot on long-term deal

- PMLiVE

EU recommendations for Gilead, Ariad and Baxter drugs

EMA backs use of HyQvia, Iclusig and Stribild

- PMLiVE

CHMP backs oral MS drugs from Sanofi, Biogen Idec

Tecfidera and Aubagio recommended for use in Europe

- PMLiVE

Otsuka’s Pletal has use restricted in Europe

EMA recommends drug only be used in limited group of patients with blood supply disorder

Sanofi reception

Follow-up data suggests long-term benefit of Sanofi’s Lemtrada in MS

Drug has a durable effect on relapse rates and disability progression

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links